Abstract 1813
Background
Few studies have compared long-term patient reported AEs of men with Prostate Cancer (PCa) treated with dose-escalation by means of BT/RT to RT (70-78 Gy) alone. In this study, we compare AEs and quality of life (QoL) between these two treatment modalities.
Methods
259 eligible men from the BT/RT cohort (2004-2011) and 123 patients (2009-2010) from a RT cohort assessed their AEs and QoL by questionnaires a minimum of 5 years after treatment. Hormonal therapy was given for 1-2 years. EPIC-26 covered urinary, sexual and bowel function and bother. The hormone domain was excluded. The SF-12 questionnaire covered QoL. The scores ranged from 0 (worst) to 100 (best). Clinical significance was set to a score difference > 10 points. Statistical significance was evaluated by Student t-test with significance level p < 0.05. Chronic fatigue was reported as percentage.
Results
Median age at survey was 74 years for both cohorts. The EPIC-26 and SF12 scores for the above domains were similar in the two cohorts with no clinical or statistical significance (Table). Chronic fatigue was higher after treatment with RT compared BT/RT, although not significantly.Table: 853P
| Measure | BT/RT Mean (SD) | RT Mean (SD) | P value |
|---|---|---|---|
| Sexual function | 27.9 (29.5) n = 255 | 20.8 (24.3) n = 120 | 0.06 |
| Sexual bother | 48.2 (37.5) n = 254 | 45.9 (34.7) n = 121 | 0.56 |
| Urinary function | 83.6 (18.0) n = 258 | 80.1 (20.5) n = 123 | 0.10 |
| Urinary irritation/obstruction | 81.3 (19.6) n = 249 | 81.8 (16.8) n = 113 | 0.80 |
| Urinary incontinence | 88.7 (18.1) n = 258 | 85.0 (22.5) n = 123 | 0.11 |
| Urinary bother | 79.9 (26.5) n = 257 | 77.6 (30.0) n = 123 | 0.47 |
| Bowel function | 86.7 (20.6) n = 254 | 83.1 (21.7) n = 121 | 0.12 |
| Bowel bother | 83.0 (25.1) n = 258 | 80.4 (26.7) n = 121 | 0.34 |
| PCS12 (SF12) | 46.4 (10.5) n = 224 | 45.1 (10.1) n = 101 | 0.30 |
| MCS12 (SF12) | 53.6 (8.0) n = 224 | 52.7 (9.2) n = 101 | 0.38 |
| Chronic fatigue | 22.0% n = 199 | 27.1% n = 86 | 0.28 |
Conclusions
Dose-escalation by means of BT/RT does not increase the AEs reported for the urinary, bowel and sexual domains of EPIC-26 or health-related QoL. Hence, BT/RT is a good treatment option for eligible patients.
Clinical trial identification
Legal entity responsible for the study
Wolfgang Lilleby.
Funding
Raagholt Foundation, Bergersen Foundation, Eckbo Foundation.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract